Preferred Label : CYP2D6 gene & CYP2C19 gene targeted mutation analysis panel:-:Pt:Bld/Tiss:-:Molgen;
LOINC status : ACTIVE;
LOINC display name : CYP2D6 gene and CYP2C19 gene targeted mutation analysis panel Molgen (Bld/Tiss);
LOINC long common name : CYP2D6 gene and CYP2C19 gene targeted mutation analysis panel - Blood or Tissue by
Molecular genetics method;
LOINC short name : CYP2D6 CYP2C19 pnl Bld/T;
LOINC description : CYP2D6 and CYP2C19 cytochrome P450 genes play a major role in the metabolism of many
widely prescribed drugs, including anti-depressants, anti-psychotics, anti-epileptics,
proton pump inhibitors, and beta-blockers. The CYP2D6 gene has at least 70 allelic
variants resulting in four phenotypic types: poor metabolizers with gene inactivation
of both alleles, intermediate metabolizers with one reduced activity allele and one
null allele, extensive metabolizers with at least one functional allele, and ultra-rapid
metabolizers with excess enzymatic activity due to multiple copies of functional alleles
from gene duplication. The CYP2C19 gene has two major variant alleles that result
in enzyme deficiency. This panel term is created for, but not limited to, Roche Diagnostics'
AmpliChip CYP450 assay, which detects 29 polymorphisms in the 2D6 and 2 polymorphisms
in the 2C19 gene, as well as gene duplications and deletions.;
Origin ID : 72886-5;
UMLS CUI : C3655037;
Has component
- Has method
- Has system
- Has time aspect
- Panel of LOINC codes
- Semantic type(s)
